Report Detail

Service & Software Global RNA-Targeted Small Molecule Drugs Market Growth (Status and Outlook) 2022-2028

  • RnM4475787
  • |
  • 03 August, 2022
  • |
  • Global
  • |
  • 111 Pages
  • |
  • LPI(LP Information)
  • |
  • Service & Software

The global market for RNA-Targeted Small Molecule Drugs is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China RNA-Targeted Small Molecule Drugs market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key RNA-Targeted Small Molecule Drugs players cover Roche, Novartis, PTC Therapeutics, Biogen and Accent Therapeutics, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global RNA-Targeted Small Molecule Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global RNA-Targeted Small Molecule Drugs market, with both quantitative and qualitative data, to help readers understand how the RNA-Targeted Small Molecule Drugs market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the RNA-Targeted Small Molecule Drugs market and forecasts the market size by Type (mRNA Translation Regulation, RNA Splicing Modification and Direct RNA Targeting), by Application (SMA, Oncology, Lung Fibrosis and Huntington's Disease), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics

Segmentation by application
SMA
Oncology
Lung Fibrosis
Huntington's Disease
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Roche
Novartis
PTC Therapeutics
Biogen
Accent Therapeutics
Anima Biotech
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics

Chapter Introduction
Chapter 1: Scope of RNA-Targeted Small Molecule Drugs, Research Methodology, etc.
Chapter 2: Executive Summary, global RNA-Targeted Small Molecule Drugs market size and CAGR, RNA-Targeted Small Molecule Drugs market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: RNA-Targeted Small Molecule Drugs revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global RNA-Targeted Small Molecule Drugs revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global RNA-Targeted Small Molecule Drugs market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global RNA-Targeted Small Molecule Drugs Market Size 2017-2028
    • 2.1.2 RNA-Targeted Small Molecule Drugs Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 RNA-Targeted Small Molecule Drugs Segment by Type
    • 2.2.1 mRNA Translation Regulation
    • 2.2.2 RNA Splicing Modification
    • 2.2.3 Direct RNA Targeting
    • 2.2.4 Indirect RNA Targeting - Epitranscriptomics
  • 2.3 RNA-Targeted Small Molecule Drugs Market Size by Type
    • 2.3.1 RNA-Targeted Small Molecule Drugs Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global RNA-Targeted Small Molecule Drugs Market Size Market Share by Type (2017-2022)
  • 2.4 RNA-Targeted Small Molecule Drugs Segment by Application
    • 2.4.1 SMA
    • 2.4.2 Oncology
    • 2.4.3 Lung Fibrosis
    • 2.4.4 Huntington's Disease
    • 2.4.5 Others
  • 2.5 RNA-Targeted Small Molecule Drugs Market Size by Application
    • 2.5.1 RNA-Targeted Small Molecule Drugs Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global RNA-Targeted Small Molecule Drugs Market Size Market Share by Application (2017-2022)

3 RNA-Targeted Small Molecule Drugs Market Size by Player

  • 3.1 RNA-Targeted Small Molecule Drugs Market Size Market Share by Players
    • 3.1.1 Global RNA-Targeted Small Molecule Drugs Revenue by Players (2020-2022)
    • 3.1.2 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Players (2020-2022)
  • 3.2 Global RNA-Targeted Small Molecule Drugs Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 RNA-Targeted Small Molecule Drugs by Regions

  • 4.1 RNA-Targeted Small Molecule Drugs Market Size by Regions (2017-2022)
  • 4.2 Americas RNA-Targeted Small Molecule Drugs Market Size Growth (2017-2022)
  • 4.3 APAC RNA-Targeted Small Molecule Drugs Market Size Growth (2017-2022)
  • 4.4 Europe RNA-Targeted Small Molecule Drugs Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas RNA-Targeted Small Molecule Drugs Market Size by Country (2017-2022)
  • 5.2 Americas RNA-Targeted Small Molecule Drugs Market Size by Type (2017-2022)
  • 5.3 Americas RNA-Targeted Small Molecule Drugs Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC RNA-Targeted Small Molecule Drugs Market Size by Region (2017-2022)
  • 6.2 APAC RNA-Targeted Small Molecule Drugs Market Size by Type (2017-2022)
  • 6.3 APAC RNA-Targeted Small Molecule Drugs Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe RNA-Targeted Small Molecule Drugs by Country (2017-2022)
  • 7.2 Europe RNA-Targeted Small Molecule Drugs Market Size by Type (2017-2022)
  • 7.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa RNA-Targeted Small Molecule Drugs by Region (2017-2022)
  • 8.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global RNA-Targeted Small Molecule Drugs Market Forecast

  • 10.1 Global RNA-Targeted Small Molecule Drugs Forecast by Regions (2023-2028)
    • 10.1.1 Global RNA-Targeted Small Molecule Drugs Forecast by Regions (2023-2028)
    • 10.1.2 Americas RNA-Targeted Small Molecule Drugs Forecast
    • 10.1.3 APAC RNA-Targeted Small Molecule Drugs Forecast
    • 10.1.4 Europe RNA-Targeted Small Molecule Drugs Forecast
    • 10.1.5 Middle East & Africa RNA-Targeted Small Molecule Drugs Forecast
  • 10.2 Americas RNA-Targeted Small Molecule Drugs Forecast by Country (2023-2028)
    • 10.2.1 United States RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.2.2 Canada RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.2.3 Mexico RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.2.4 Brazil RNA-Targeted Small Molecule Drugs Market Forecast
  • 10.3 APAC RNA-Targeted Small Molecule Drugs Forecast by Region (2023-2028)
    • 10.3.1 China RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.3.2 Japan RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.3.3 Korea RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.3.4 Southeast Asia RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.3.5 India RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.3.6 Australia RNA-Targeted Small Molecule Drugs Market Forecast
  • 10.4 Europe RNA-Targeted Small Molecule Drugs Forecast by Country (2023-2028)
    • 10.4.1 Germany RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.4.2 France RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.4.3 UK RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.4.4 Italy RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.4.5 Russia RNA-Targeted Small Molecule Drugs Market Forecast
  • 10.5 Middle East & Africa RNA-Targeted Small Molecule Drugs Forecast by Region (2023-2028)
    • 10.5.1 Egypt RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.5.2 South Africa RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.5.3 Israel RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.5.4 Turkey RNA-Targeted Small Molecule Drugs Market Forecast
    • 10.5.5 GCC Countries RNA-Targeted Small Molecule Drugs Market Forecast
  • 10.6 Global RNA-Targeted Small Molecule Drugs Forecast by Type (2023-2028)
  • 10.7 Global RNA-Targeted Small Molecule Drugs Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Roche
    • 11.1.1 Roche Company Information
    • 11.1.2 Roche RNA-Targeted Small Molecule Drugs Product Offered
    • 11.1.3 Roche RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Roche Main Business Overview
    • 11.1.5 Roche Latest Developments
  • 11.2 Novartis
    • 11.2.1 Novartis Company Information
    • 11.2.2 Novartis RNA-Targeted Small Molecule Drugs Product Offered
    • 11.2.3 Novartis RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Novartis Main Business Overview
    • 11.2.5 Novartis Latest Developments
  • 11.3 PTC Therapeutics
    • 11.3.1 PTC Therapeutics Company Information
    • 11.3.2 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 PTC Therapeutics Main Business Overview
    • 11.3.5 PTC Therapeutics Latest Developments
  • 11.4 Biogen
    • 11.4.1 Biogen Company Information
    • 11.4.2 Biogen RNA-Targeted Small Molecule Drugs Product Offered
    • 11.4.3 Biogen RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Biogen Main Business Overview
    • 11.4.5 Biogen Latest Developments
  • 11.5 Accent Therapeutics
    • 11.5.1 Accent Therapeutics Company Information
    • 11.5.2 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Accent Therapeutics Main Business Overview
    • 11.5.5 Accent Therapeutics Latest Developments
  • 11.6 Anima Biotech
    • 11.6.1 Anima Biotech Company Information
    • 11.6.2 Anima Biotech RNA-Targeted Small Molecule Drugs Product Offered
    • 11.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Anima Biotech Main Business Overview
    • 11.6.5 Anima Biotech Latest Developments
  • 11.7 Arrakis Pharmaceuticals
    • 11.7.1 Arrakis Pharmaceuticals Company Information
    • 11.7.2 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Offered
    • 11.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Arrakis Pharmaceuticals Main Business Overview
    • 11.7.5 Arrakis Pharmaceuticals Latest Developments
  • 11.8 Epics Therapeutics
    • 11.8.1 Epics Therapeutics Company Information
    • 11.8.2 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Epics Therapeutics Main Business Overview
    • 11.8.5 Epics Therapeutics Latest Developments
  • 11.9 Expansion Therapeutics
    • 11.9.1 Expansion Therapeutics Company Information
    • 11.9.2 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Expansion Therapeutics Main Business Overview
    • 11.9.5 Expansion Therapeutics Latest Developments
  • 11.10 Gotham Therapeutics
    • 11.10.1 Gotham Therapeutics Company Information
    • 11.10.2 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Gotham Therapeutics Main Business Overview
    • 11.10.5 Gotham Therapeutics Latest Developments
  • 11.11 H3 Biomedicine
    • 11.11.1 H3 Biomedicine Company Information
    • 11.11.2 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Offered
    • 11.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 H3 Biomedicine Main Business Overview
    • 11.11.5 H3 Biomedicine Latest Developments
  • 11.12 Ribometrix
    • 11.12.1 Ribometrix Company Information
    • 11.12.2 Ribometrix RNA-Targeted Small Molecule Drugs Product Offered
    • 11.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.12.4 Ribometrix Main Business Overview
    • 11.12.5 Ribometrix Latest Developments
  • 11.13 Skyhawk Therapeutics
    • 11.13.1 Skyhawk Therapeutics Company Information
    • 11.13.2 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.13.4 Skyhawk Therapeutics Main Business Overview
    • 11.13.5 Skyhawk Therapeutics Latest Developments
  • 11.14 STORM Therapeutics
    • 11.14.1 STORM Therapeutics Company Information
    • 11.14.2 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.14.4 STORM Therapeutics Main Business Overview
    • 11.14.5 STORM Therapeutics Latest Developments
  • 11.15 Twentyeight-Seven Therapeutics
    • 11.15.1 Twentyeight-Seven Therapeutics Company Information
    • 11.15.2 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Offered
    • 11.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Gross Margin and Market Share (2020-2022)
    • 11.15.4 Twentyeight-Seven Therapeutics Main Business Overview
    • 11.15.5 Twentyeight-Seven Therapeutics Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on RNA-Targeted Small Molecule Drugs. Industry analysis & Market Report on RNA-Targeted Small Molecule Drugs is a syndicated market report, published as Global RNA-Targeted Small Molecule Drugs Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of RNA-Targeted Small Molecule Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,034.14
6,068.28
3,601.44
7,202.88
494,100.00
988,200.00
290,201.40
580,402.80
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report